Phase 2
Intervention Type
Intravenous (IV) Injection
Funder Type
Organization | University

Drug Details

Clazakizumab is a genetically engineered humanized IgG1 monoclonal antibody (mAb) that binds with high affinity to human IL-6.

Study Purpose

In this study, clazakizumab will be administered to patients with life-threatening COVID-19 infection manifest by pulmonary failure and a clinical picture consistent with a cytokine storm syndrome. This is a single-center randomized, double-blind, placebo-controlled trial in which 30 patients will be enrolled and randomly assigned in a 1:1:1 ratio to three study arms that will receive clazakizumab at a dose of 12.5 mg, 25 mg or placebo.

Find a Clinical Trial


footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >